Literature DB >> 22659571

Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function.

Joel A Cassel1, Mark E McDonnell, Venkata Velvadapu, Vyacheslav Andrianov, Allen B Reitz.   

Abstract

Dysfunction of the heterogeneous ribonucleoprotein TAR DNA binding protein 43 (TDP-43) is associated with neurodegeneration in diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Here we examine the effects of a series of 4-aminoquinolines with affinity for TDP-43 upon caspase-7-induced cleavage of TDP-43 and TDP-43 cellular function. These compounds were mixed inhibitors of biotinylated TG6 binding to TDP-43, binding to both free and occupied TDP-43. Incubation of TDP-43 and caspase-7 in the presence of these compounds stimulated caspase-7 mediated cleavage of TDP-43. This effect was antagonized by the oligonucleotide TG12, prevented by denaturing TDP-43, and exhibited a similar relation of structure to function as for the displacement of bt-TG6 binding to TDP-43. In addition, the compounds did not affect caspase-7 enzyme activity. In human neuroglioma H4 cells, these compounds lowered levels of TDP-43 and increased TDP-43 C-terminal fragments via a caspase-dependent mechanism. Subsequent experiments demonstrated that this was due to induction of caspases 3 and 7 leading to increased PARP cleavage in H4 cells with similar rank order of the potency among the compounds tests for displacement of bt-TG6 binding. Exposure to these compounds also reduced HDAC-6, ATG-7, and increased LC3B, consistent with the effects of TDP-43 siRNA described by other investigators. These data suggest that such compounds may be useful biochemical probes to further understand both the normal and pathological functions of TDP-43, and its cleavage and metabolism promoted by caspases.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659571      PMCID: PMC3402613          DOI: 10.1016/j.biochi.2012.05.020

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  34 in total

1.  Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA.

Authors:  Sang Hwa Kim; Naval P Shanware; Michael J Bowler; Randal S Tibbetts
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Regulation of autophagy by neuropathological protein TDP-43.

Authors:  Jayarama Krishnan Bose; Chi-Chen Huang; C-K James Shen
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

Review 3.  Current nervous system related drug targets for the treatment of amyotrophic lateral sclerosis.

Authors:  Aaron C Pawlyk; Joel A Cassel; Allen B Reitz
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

4.  TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1.

Authors:  Karli K McDonald; Anaïs Aulas; Laurie Destroismaisons; Sarah Pickles; Evghenia Beleac; William Camu; Guy A Rouleau; Christine Vande Velde
Journal:  Hum Mol Genet       Date:  2011-01-21       Impact factor: 6.150

5.  Development of a novel nonradiometric assay for nucleic acid binding to TDP-43 suitable for high-throughput screening using AlphaScreen technology.

Authors:  Joel A Cassel; Benjamin E Blass; Allen B Reitz; Aaron C Pawlyk
Journal:  J Biomol Screen       Date:  2010-09-20

6.  TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage.

Authors:  Hiroaki Suzuki; Kikyo Lee; Masaaki Matsuoka
Journal:  J Biol Chem       Date:  2011-02-21       Impact factor: 5.157

Review 7.  TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Robert H Baloh
Journal:  FEBS J       Date:  2011-08-24       Impact factor: 5.542

8.  Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance.

Authors:  Emanuele Buratti; Antonia Brindisi; Franco Pagani; Francisco E Baralle
Journal:  Am J Hum Genet       Date:  2004-06       Impact factor: 11.025

9.  Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9.

Authors:  E Buratti; F E Baralle
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

10.  Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping.

Authors:  E Buratti; T Dörk; E Zuccato; F Pagani; M Romano; F E Baralle
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

View more
  10 in total

1.  Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines.

Authors:  Joel A Cassel; Allen B Reitz
Journal:  Biochim Biophys Acta       Date:  2013-03-27

2.  Small Molecule Targeting TDP-43's RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS).

Authors:  Liberty François-Moutal; Razaz Felemban; David D Scott; Melissa R Sayegh; Victor G Miranda; Samantha Perez-Miller; Rajesh Khanna; Vijay Gokhale; Daniela C Zarnescu; May Khanna
Journal:  ACS Chem Biol       Date:  2019-08-27       Impact factor: 5.100

3.  Fragile X protein mitigates TDP-43 toxicity by remodeling RNA granules and restoring translation.

Authors:  Alyssa N Coyne; Shizuka B Yamada; Bhavani Bagevalu Siddegowda; Patricia S Estes; Benjamin L Zaepfel; Jeffrey S Johannesmeyer; Donovan B Lockwood; Linh T Pham; Michael P Hart; Joel A Cassel; Brian Freibaum; Ashley V Boehringer; J Paul Taylor; Allen B Reitz; Aaron D Gitler; Daniela C Zarnescu
Journal:  Hum Mol Genet       Date:  2015-09-18       Impact factor: 6.150

4.  Caspase-4 mediates cytoplasmic accumulation of TDP-43 in the primate brains.

Authors:  Peng Yin; Xiangyu Guo; Weili Yang; Sen Yan; Su Yang; Ting Zhao; Qiang Sun; Yunbo Liu; Shihua Li; Xiao-Jiang Li
Journal:  Acta Neuropathol       Date:  2019-02-27       Impact factor: 17.088

Review 5.  Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis.

Authors:  Archana Prasad; Vidhya Bharathi; Vishwanath Sivalingam; Amandeep Girdhar; Basant K Patel
Journal:  Front Mol Neurosci       Date:  2019-02-14       Impact factor: 5.639

6.  Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells.

Authors:  Yumna H Shabaik; Melissa Millard; Nouri Neamati
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

7.  Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS).

Authors:  Allison S Limpert; Margrith E Mattmann; Nicholas D P Cosford
Journal:  Beilstein J Org Chem       Date:  2013-04-15       Impact factor: 2.883

8.  Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB.

Authors:  Ying Hu; Wenjie Ge; Xingwen Wang; Gopinath Sutendra; Kunming Zhao; Zinaida Dedeić; Elizabeth A Slee; Caroline Baer; Xin Lu
Journal:  Oncotarget       Date:  2015-12-15

Review 9.  Proteotoxicity and Neurodegenerative Diseases.

Authors:  Clara Ruz; Jose Luis Alcantud; Francisco Vives Montero; Raquel Duran; Sara Bandres-Ciga
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

Review 10.  Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis.

Authors:  Yvonne E Klingl; Donya Pakravan; Ludo Van Den Bosch
Journal:  Br J Pharmacol       Date:  2020-08-26       Impact factor: 9.473

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.